Albertson's LLC, a nationwide supermarket chain with more than 200 stores, has announced that it will participate in the Diabetes Control Program (DCP) of the Diabetes Prevention and Control Alliance. The DCP works through trained pharmacists to provide education and support to people with diabetes.
Novo Nordisk, the world's largest insulin manufacturer, has joined the Diabetes Prevention and Control Alliance (DPCA), a group whose goals are to reduce people's risk of developing diabetes and to work with people who already have it.
RALEIGH, NC- DiabetesSisters is pleased to announce that registration for the 2011 Weekend for Women Conference in Raleigh, NC will open on January 1, 2011 at 8am. The Conference, a revolutionary national weekend conference designed specifically for women with diabetes, will take place April 29 - May 1, 2011 at the Marriott City Center in downtown Raleigh.
Novo Nordisk, a world leader in diabetes care, has partnered with Chip Ganassi Racing, LLC to create the Novo Nordisk Chip Ganassi Racing team for the 2011 IZOD IndyCar season. The team will sponsor a new entry in the series driven by American racecar driver Charlie Kimball. This partnership makes Kimball one of the first drivers from the 2010 Firestone Indy Lights series to move up the official "Road to Indy" with a full season sponsorship.
Leaders of the Medicare Diabetes Screening Project (MDSP) announced that twenty community-based organizations from 17 states were given awards of $2,500 each to be used to encourage seniors ages 65 and older who are covered under Medicare to get screened for diabetes.
Novo Nordisk announced today the availability of NovoDoseTM - the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk's modern insulin analog portfolio: Levemir® (insulin detemir [rDNA origin] injection), NovoLog® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).
Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.